Can Fite Biopharma Stock Performance
| CANF Stock | USD 1.63 0.07 4.49% |
On a scale of 0 to 100, Can Fite holds a performance score of 5. The firm shows a Beta (market volatility) of 0.48, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Can Fite's returns are expected to increase less than the market. However, during the bear market, the loss of holding Can Fite is expected to be smaller as well. Please check Can Fite's total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether Can Fite's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Can Fite Biopharma are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite nearly unsteady basic indicators, Can Fite reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 3 M |
Can |
Can Fite Relative Risk vs. Return Landscape
If you would invest 142.00 in Can Fite Biopharma on December 17, 2024 and sell it today you would earn a total of 21.00 from holding Can Fite Biopharma or generate 14.79% return on investment over 90 days. Can Fite Biopharma is currently generating 0.3141% in daily expected returns and assumes 4.2267% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Can, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Can Fite Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Can Fite's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Can Fite Biopharma, and traders can use it to determine the average amount a Can Fite's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0743
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CANF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.23 actual daily | 37 63% of assets are more volatile |
Expected Return
| 0.31 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Can Fite is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Can Fite by adding it to a well-diversified portfolio.
Can Fite Fundamentals Growth
Can Stock prices reflect investors' perceptions of the future prospects and financial health of Can Fite, and Can Fite fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Can Stock performance.
| Return On Equity | -1.58 | ||||
| Return On Asset | -0.57 | ||||
| Operating Margin | (12.96) % | ||||
| Current Valuation | 4.81 M | ||||
| Shares Outstanding | 6.1 M | ||||
| Price To Earning | (3.41) X | ||||
| Price To Book | 4.01 X | ||||
| Price To Sales | 14.90 X | ||||
| Revenue | 743 K | ||||
| EBITDA | (8.18 M) | ||||
| Cash And Equivalents | 12.77 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 40 K | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (8.44 M) | ||||
| Earnings Per Share | (2.60) X | ||||
| Total Asset | 9.99 M | ||||
| Retained Earnings | (158.48 M) | ||||
| Current Asset | 39.51 M | ||||
| Current Liabilities | 5.77 M | ||||
About Can Fite Performance
By analyzing Can Fite's fundamental ratios, stakeholders can gain valuable insights into Can Fite's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Can Fite has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Can Fite has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. Can-Fite Biopharma operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 8 people.Things to note about Can Fite Biopharma performance evaluation
Checking the ongoing alerts about Can Fite for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Can Fite Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Can Fite Biopharma may become a speculative penny stock | |
| Can Fite Biopharma had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 743 K. Net Loss for the year was (7.63 M) with profit before overhead, payroll, taxes, and interest of 667 K. | |
| Can Fite Biopharma currently holds about 12.77 M in cash with (8.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.47. | |
| Can Fite Biopharma has a poor financial position based on the latest SEC disclosures |
- Analyzing Can Fite's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Can Fite's stock is overvalued or undervalued compared to its peers.
- Examining Can Fite's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Can Fite's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Can Fite's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Can Fite's stock. These opinions can provide insight into Can Fite's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Can Stock analysis
When running Can Fite's price analysis, check to measure Can Fite's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Can Fite is operating at the current time. Most of Can Fite's value examination focuses on studying past and present price action to predict the probability of Can Fite's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Can Fite's price. Additionally, you may evaluate how the addition of Can Fite to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |